CD16A and CD16B mRNA levels as a potential immunological marker in prostate cancer

Introduction and purpose Understanding the movement of immune cells in prostate cancer is the best solution for development antitumor therapy. In our study, we will evaluate level mRNA CD16А (FCGR3A) and mRNA CD16B (FCGR3B) in patients diagnosing benign hyperplasia and patients diagnosing prostate cancer (Pc). Materials and methods In the study, we analyzed 240 samples of mRNA, 49 was the blood of healthy donors, 37 was the blood of prostate cancer patients and 62 tumors of prostate, 37 were blood of hyperplasia and 55 was tissue of hyperplasia, all patients treated in the Hospital 33 (Niznhy Novgord, Russia). The relative level of mRNA in peripheral blood and tumors was determined by the method of reverse transcription-polymerase chain reaction in real time. Results In the peripheral blood of patients with prostate cancer and patients with hyperplasia, the level of mRNA FCGR3A and FCGR3B was statistically significantly lower than in healthy individuals. The normalization of the CD16 level in the blood of healthy donors was higher The relative level of mRNA FCGR3A, FCGR3B was the highest in patients with Prostate antigen specific (PSA) from 10Ng/ml to 20Ng/ml. The higher level mRNA FCGR3A and FCGR3B was for patients with higher testosterone ≥8mmol/L. also a higher level of FCGR3A, FCGR3B was found in patients diagnosed with an adenopathy:, a higher size prostate and a higher Gleason Scores. The results of Classification based on the degree of differentiation shows that the level of mRNA FCGR3A and FCGR3B in patients with medium differentiation was higher and statistically significant than in patient with lower differentiation. Conclusion. The Changes in the mRNA level of genes encoding CD16A (FCGR3A) and CD16B (FCGR3A) was detected in blood and tumor samples. The results indicate the potential use of these indicators as monitoring immunological markers in hyperplasia and prostate cancer.

Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer

Purpose: this report provides information about clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer in the Regional Hospital from Trujillo, Peru. Materials and Methods: retrospective, descriptive observation study of all the clinical histories from patients with histopathology diagnosis of prostate cancer during the period of January 2000 - December 2004. The sample was constituted by 60 patients with clinics histories, study by image based on the prostate ecography and the prostate specific antigen results. The average of age found was of 75.4 years old; the most frequent clinical case reported a 91.6% of patients with obstructive and irritative symptoms. In the levels of prostate antigen the PSA found values between 10-50 ng/ml, in 48.78% of the patients. In the ecography prostate study there where evidence of hypoecogenic images in 56%, hyperecogenics images 12%, heterogenics images 20% and 12% homogenics images. In the TNM classification the higher percentage is located in T stage with an 81.67%, and in smaller proportions in the N1 and M1 stages with 8.33% and 10.0% respectively. According to Gleason it was found levels from 2-4 with 36.67%, in the level 5-7 with 23.33% and in the level 8-10 with 40.0%. Conclusions: All the patients with prostate cancer showed a clinical symptoms about, obstructive and irritative and in other organs a less percentage of symptoms that shows metastases; in more than a half of the patients, the digital rectal examination showed nodules and irregularities in its surface; in the prostate ecography it is report a higher percentage of hypoecogenics images suggestive of neoplasia. The levels of specific prostate antigen in more than 70% of the patients where over of 10 ng/ml; in the totally of the patients the histological type most frequent is the Adenocarcinoma, with a high grade of percentage of patients who had been bad prognosticated according to the Gleason score. According the NTM, more of the two thirds parts of patients with prostate cancer are in T stage, with a high percentage extending on the prostatic capsule.